Jina Kim is Director of the Ab Technology Discovery Group at Samsung Biologics. Her team developed novel bispecific antibody platforms for therapeutic use. She has over 10 years of experience in drug development, especially oncology. At Samsung Biologics, Jina focuses on development of bispecific antibodies and antibody engineering. She has a strong interest in the development of new bispecific antibodies for easier control and more versatility.